Literature DB >> 11549451

Selective, orally active MMP inhibitors with an aryl backbone.

T E Barta1, D P Becker, L J Bedell, G A De Crescenzo, J J McDonald, P Mehta, G E Munie, C I Villamil.   

Abstract

This letter describes SAR exploration and rat PK optimization of a series of novel, MMP-1 sparing aryl hydroxamate sulfonamides with activity against MMP-2 and MMP-13.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549451     DOI: 10.1016/s0960-894x(01)00487-5

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo.

Authors:  Jiahua Jiang; Anita Thyagarajan-Sahu; Viktor Krchňák; Andrej Jedinak; George E Sandusky; Daniel Sliva
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.